Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript Summary
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript Summary
Biosecurity business recorded $14 million in revenue at a 28% gross margin, indicating a decline.The following is a summary of the Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript:
以下是Ginkgo Bioworks Holdings, Inc. (DNA) 2024年第三季度業績會交易摘要:
Financial Performance:
財務表現:
Ginkgo Bioworks reported a cash position of $616 million with no bank debt, exceeding their cost-cutting target for 2024.
Cell engineering business recognized $45 million in noncash revenue due to the termination of a customer agreement, with underlying revenue at $30 million, down 20% year-over-year.
Biosecurity business recorded $14 million in revenue at a 28% gross margin, indicating a decline.
Adjusted EBITDA improved to negative $20 million from negative $84 million in Q3 2023.
Ginkgo Bioworks報告現金頭寸爲61600萬美元，並無銀行債務，超過了他們2024年的削減成本目標。
電芯工程業務因客戶協議終止而確認非現金營業收入4500萬美元，基礎營業收入爲3000萬美元，同比下降20%。
生物安全業務錄得1400萬美元的營業收入，毛利率爲28%，顯示下降。
調整後的EBITDA從2023年第三季度的8400萬美元負值改善至2000萬美元負值。
Business Progress:
業務進展：
Ginkgo Bioworks continues to transition from small early-stage customers to larger enterprise customers, actively engaging in 136 programs across 81 customers.
The company has launched new data points business, signing deals with top biopharma companies, indicating rapid traction in the market.
Expanded collaboration with existing customers like Merck and Novo Nordisk, reaching significant milestones and enlarging the scope of ongoing projects.
Consolidation efforts include closing various international sites and transitioning to fewer locations, significantly ahead of schedule.
Ginkgo Bioworks繼續從小型初創客戶轉向更大型企業客戶，積極參與81名客戶的136個項目。
公司推出了新的數據點業務，與頂級生物製藥公司簽署了合作協議，表明市場迅速獲得了增長。
擴大與默沙東和諾和諾德等現有客戶的合作，達成重要里程碑，並擴大了正在進行項目的範圍。
整合工作包括關閉各個國際地點，轉移至更少的地點，進度大大超前。
Opportunities:
機會：
The launch of the data points business presents a new revenue stream, particularly in biopharma, enhancing Ginkgo's service offerings to include extensive data sets for AI model training.
Active engagement in the biosecurity market, particularly with the spread of H5N1, positions Ginkgo to potentially partner with the government and private sectors for disease surveillance and biosecurity solutions.
數據點業務的推出爲新的營業收入來源，特別是在生物製藥領域，增強了銀杏的服務內容，包括爲人工智能模型訓練提供廣泛的數據集。
積極參與生物安全市場，特別是隨着H5N1的傳播，將銀杏定位爲潛在與政府和私營部門合作進行疾病監測和生物安全解決方案的合作伙伴。
Risks:
風險：
Shift towards larger enterprise customers and away from early-stage customers could impact market diversity and income stability.
Continued restructuring efforts might lead to operational disruptions and impact employee morale and retention.
向更大的企業客戶轉變，遠離早期客戶，可能影響市場多樣性和收入穩定性。
持續的重組努力可能會導致業務中斷，影響員工士氣和留任率。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
